Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
4
The Technology Select Sector SPDR® Fund
XLK
5
Direxion Daily Financial Bull 3X Shares ETF
FAS
CN Stock MarketDetailed Quotes
BeOne Medicines Ltd. (688235)
- 234.80
- -1.51-0.64%
Market Closed Apr 30 15:00 CST
361.93BMarket Cap247.68P/E (TTM)
237.97High232.05Low2.54MlotVolume236.00Open236.31Prev Close594.88MTurnover2.20%Turnover Ratio247.68P/E (Static)1.54BShares346.0052wk High11.81P/B27.01BFloat Cap213.3352wk Low283.57Limit Up115.06MShs Float346.00Historical High189.05Limit Down2.51%Range %82.00Historical Low--Dividend TTM234.56Avg Price1.36MlotAsk--Div Yield TTM1Lot Size1.06MlotBid
688235 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
688235 Orderflow
Unit: --
688235 Orderflow Trend
IntradayDayWeekMonth
No Data
BeOne Medicines Ltd. (688235) News
Express News | Huahui Health: Beone Medicines Will Pay Huahui Health an Upfront Payment of USD 20 Mln
Express News | Huahui Health and Beone Medicines Enter Into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug Hh160
Beigene (06160.HK) will release its financial report on May 6.
Beigene (06160.HK) will release its earnings report on May 6. Investors are advised to stay tuned. What about the previous performance? Beigene (06160.HK) reported Q4 2025 revenue of $1.498 billion, net profit of $66.502 million, and earnings per share of $0.04. Q1 2025 revenue was $1.117 billion, with a net profit of $1.27 million. NiuNiu Reminder: 1. There is no mandatory regulation regarding the division of fiscal years for Hong Kong-listed and US-listed companies; it is entirely determined by the company itself. Therefore, each financial reporting period can serve as the company's annual report cutoff date.
FDA Grants Priority Review To BeOne Medicines' Supplemental Biologics License Application For Tevimbra (Tislelizumab) In Combination With Ziihera (Zanidatamab) And Chemotherapy For Untreated Unresectable Locally Advanced/Metastatic HER2-positive...
Orient Securities: As the ASCO event approaches, China's innovative drug sector is making a strong breakthrough.
Recently, the official theme of the 2026 ASCO conference was announced, which is expected to significantly enhance the academic value, clinical value, and global competitiveness of domestically innovative drugs.
BeOne Medicines Posts U.S. Proxy Materials, Highlights Cross-Border Disclosure
BeOne Medicines Ltd. (688235) Stock Forum
Morning Movers
Gapping Up
$Lumentum (LITE.US)$ climbed 4.88% in premarket trading after Nvidia invested 2 billion in Marvell and announced a strategic partnership that boosted sentiment for AI optical interconnect suppliers.
$Newmont (NEM.US)$ climbed 3.93% in premarket trading due to a rebound in gold prices on easing Middle East tensions and remarks from Fed Chair Powell signaling no need for rate hikes.
$Ciena (CIEN.US)$ clim...
Gapping Up
$Lumentum (LITE.US)$ climbed 4.88% in premarket trading after Nvidia invested 2 billion in Marvell and announced a strategic partnership that boosted sentiment for AI optical interconnect suppliers.
$Newmont (NEM.US)$ climbed 3.93% in premarket trading due to a rebound in gold prices on easing Middle East tensions and remarks from Fed Chair Powell signaling no need for rate hikes.
$Ciena (CIEN.US)$ clim...
8
1
Morning Movers
Gapping Up
$Fitness Champs (FCHL.US)$ soared 122.81% in premarket trading after implementing a fifteen for one reverse share split to regain Nasdaq minimum bid compliance.
$EpicQuest Education (EEIQ.US)$ soared 59.33% in premarket trading.
$Olaplex (OLPX.US)$ soared 50.38% in premarket trading after Henkel agreed to acquire Olaplex for 2.06 dollars per share in cash a roughly 55 percent premium to the prior clos...
Gapping Up
$Fitness Champs (FCHL.US)$ soared 122.81% in premarket trading after implementing a fifteen for one reverse share split to regain Nasdaq minimum bid compliance.
$EpicQuest Education (EEIQ.US)$ soared 59.33% in premarket trading.
$Olaplex (OLPX.US)$ soared 50.38% in premarket trading after Henkel agreed to acquire Olaplex for 2.06 dollars per share in cash a roughly 55 percent premium to the prior clos...
8
Below is 2/10 P/L with a ~50/50 holding of $BeiGene (ONC.US)$ and $Tencent Music (TME.US)$.
Just transferred some random stocks in and this is largely the performance of those stocks (two ADRs listed in US exchange). Would love to see how to add some FX and currency element into current portfolio. App looks fun and interesting to use, or just to look at and kill some time. New year strategy is mainly to stay the course and don't trade too much. Depending on the market or policy mov...
Just transferred some random stocks in and this is largely the performance of those stocks (two ADRs listed in US exchange). Would love to see how to add some FX and currency element into current portfolio. App looks fun and interesting to use, or just to look at and kill some time. New year strategy is mainly to stay the course and don't trade too much. Depending on the market or policy mov...
2
Morning Movers
Gapping Up
$Immunome (IMNM.US)$ surged 23.1% in premarket trading after announcing positive Phase 3 results for varegacestat in desmoid tumors including a significant improvement in progression free survival versus placebo and a 56 percent objective response rate.
$Canopy Growth (CGC.US)$ increased 5.17% in premarket trading due to reports that President Trump is expected to sign an executive order reclassifying...
Gapping Up
$Immunome (IMNM.US)$ surged 23.1% in premarket trading after announcing positive Phase 3 results for varegacestat in desmoid tumors including a significant improvement in progression free survival versus placebo and a 56 percent objective response rate.
$Canopy Growth (CGC.US)$ increased 5.17% in premarket trading due to reports that President Trump is expected to sign an executive order reclassifying...
12
3
1
Morning Movers
Gapping Up
$Olema Pharmaceuticals (OLMA.US)$ soared 313.26% in premarket trading after Roche reported that giredestrant met its primary endpoint in a Phase 3 adjuvant trial for ER positive HER2 negative early stage breast cancer raising optimism for Olema palazestrant.
$Can-Fite BioPharma (CANF.US)$ soared 46.1% in premarket trading after announcing ongoing enrollment in a pivotal Phase III trial of Namodenoson for ...
Gapping Up
$Olema Pharmaceuticals (OLMA.US)$ soared 313.26% in premarket trading after Roche reported that giredestrant met its primary endpoint in a Phase 3 adjuvant trial for ER positive HER2 negative early stage breast cancer raising optimism for Olema palazestrant.
$Can-Fite BioPharma (CANF.US)$ soared 46.1% in premarket trading after announcing ongoing enrollment in a pivotal Phase III trial of Namodenoson for ...
8
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)